Division of Metabolic Diseases, Department of Pediatric Specialties, Bambino Gesù Children's Hospital, Rome, Italy.
Medical Genetics Unit, Medical Genetics Laboratory, Bambino Gesù Children's Hospital, Rome, Italy.
J Pediatr. 2018 Nov;202:272-278.e4. doi: 10.1016/j.jpeds.2018.06.050. Epub 2018 Sep 5.
To evaluate the role of next generation sequencing in genetic diagnosis of pediatric patients with persistent hypoglycemia.
Sixty-four patients investigated through an extensive workup were divided in 3 diagnostic classes based on the likelihood of a genetic diagnosis: (1) single candidate gene (9/64); (2) multiple candidate genes (43/64); and (3) no candidate gene (12/64). Subsequently, patients were tested through a custom gene panel of 65 targeted genes, which included 5 disease categories: (1) hyperinsulinemic hypoglycemia, (2) fatty acid-oxidation defects and ketogenesis defects, (3) ketolysis defects, (4) glycogen storage diseases and other disorders of carbohydrate metabolism, and (5) mitochondrial disorders. Molecular data were compared with clinical and biochemical data.
A proven diagnosis was obtained in 78% of patients with suspicion for a single candidate gene, in 49% with multiple candidate genes, and in 33% with no candidate gene. The diagnostic yield was 48% for hyperinsulinemic hypoglycemia, 66% per fatty acid-oxidation and ketogenesis defects, 59% for glycogen storage diseases and other carbohydrate disorders, and 67% for mitochondrial disorders.
This approach provided a diagnosis in ~50% of patients in whom clinical and laboratory evaluation did not allow identification of a single candidate gene and a diagnosis was established in 33% of patients belonging to the no candidate gene class. Next generation sequencing technique is cost-effective compared with Sanger sequencing of multiple genes and represents a powerful tool for the diagnosis of inborn errors of metabolism presenting with persistent hypoglycemia.
评估下一代测序在儿童持续性低血糖症遗传诊断中的作用。
通过广泛的检查,将 64 例患者分为 3 个诊断类别,基于遗传诊断的可能性:(1)单候选基因(9/64);(2)多个候选基因(43/64);(3)无候选基因(12/64)。随后,通过 65 个靶向基因的定制基因panel 对患者进行检测,该panel 包括 5 种疾病类别:(1)高胰岛素血症性低血糖症;(2)脂肪酸氧化缺陷和酮体生成缺陷;(3)酮体分解缺陷;(4)糖原贮积病和其他碳水化合物代谢障碍;(5)线粒体疾病。将分子数据与临床和生化数据进行比较。
在疑似单候选基因的患者中,有 78%获得了明确诊断,在疑似多个候选基因的患者中,有 49%获得了明确诊断,在疑似无候选基因的患者中,有 33%获得了明确诊断。高胰岛素血症性低血糖症的诊断率为 48%,脂肪酸氧化和酮体生成缺陷为 66%,糖原贮积病和其他碳水化合物代谢障碍为 59%,线粒体疾病为 67%。
这种方法为~50%的临床和实验室评估无法确定单一候选基因的患者提供了诊断,为属于无候选基因类别的 33%的患者建立了诊断。与多个基因的 Sanger 测序相比,下一代测序技术具有成本效益,是诊断持续性低血糖症的遗传代谢缺陷的有力工具。